hepatocellular carcinoma (10) (11) (12) (13) . Biopsy is currently the gold standard for advanced fi brosis diagnosis in NAFLD patients, but is invasive, has high inter-observer variability, and is associated with adverse side eff ects including bleeding, pain, and even death ( 14, 15 ) . Th ere is a strong need for the noninvasive diagnosis of advanced fi brosis in NAFLD patients.
Th ere is a well-established need for accurate, noninvasive, and commercially available tests to diagnose NAFLD-associated advanced fi brosis. Noninvasive markers such as Cytokeratin-18 (ref. 16 ), NAFLD fi brosis score ( 17 ) , FIB-4 (ref. 18 ) , and Enhanced Liver Fibrosis ( 19 ) may not be accurate enough for routine clinical use in all patients ( 1, 20, 21 ) . Ultrasound-based methods, including acoustic radiation force impulse imaging and transient elastography (FibroScan), have high (21-50%) failure rates in NAFLD patients (22) (23) (24) (25) . Magnetic resonance elastography (MRE) is a novel magnetic resonance technique utilizing shear waves to characterize liver fi brosis. A special magnetic resonance imaging (MRI) technique is used to image propagating mechanical waves in tissue and these images are processed with an algorithm to generate cross-sectional images that quantitatively depict tissue stiff ness. In general, it is necessary to image the pattern of propagating waves in three dimensions (3D) in order to properly calculate tissue stiff ness. However, commercial implementations of hepatic MRE that are currently available use hardware designed to generate mechanical waves that propagate transversely in the liver and special processing algorithms that allow valid stiff ness measurements to be obtained using single two-dimensional (2D) axial images of the wave pattern. Two-dimensional MRE (2D-MRE) is less demanding from an instrumentation standpoint than 3D-MRE and is the approach that is currently used in commercially available versions of MRE because it can be easily implemented on basic MRI systems. 2D-MRE has been prospectively shown to be highly accurate for advanced fi brosis diagnosis (26) (27) (28) . Although technically more demanding, 3D-MRE off ers advantages that might provide even higher diagnostic performance.
Utilizing a prospective study design, we compared the accuracy of 3D-MRE and 2D-MRE for diagnosing advanced fi brosis in a cohort of patients with biopsy-confi rmed NAFLD. We also compared the accuracy of 3D-MRE and 2D-MRE for diagnosing other stages of fi brosis in NAFLD patients and for diagnosing NASH.
METHODS

Design
Th is is a cross-sectional analysis of a prospective cohort consisting of 100 consecutive patients with biopsy-proven NAFLD who underwent 2D-MRE and 3D-MRE imaging. Liver biopsies were obtained for clinical care and MRIs were obtained for research. Aft er undergoing careful exclusion for other causes of liver diseases and secondary causes of hepatic steatosis, patients attended a research clinic visit for standardized history, physical exam, anthropometric exam, and biochemical testing at the University of California at San Diego (UCSD) NAFLD Translational Research Unit (29) (30) (31) (32) (33) and an imaging visit at the UCSD MR3T Research Laboratory for 2D-and 3D-MRE. Informed consent was obtained from all patients. Th is study was approved by the UCSD Institutional Review Board and the UCSD Clinical and Translational Research Institute.
Inclusion/exclusion criteria
Patients ≥18 years old with biopsy-confi rmed NAFLD and written informed consent who did not meet any exclusion criteria were included in the study. Exclusion criteria included: regular and excessive alcohol consumption within 2 years of recruitment (≥14 drinks/week for men or ≥7 drinks/week for women), use of hepatotoxic drugs or drugs known to cause hepatic steatosis, clinical or laboratory evidence of secondary NAFLD due to major nutritional and iatrogenic gastrointestinal disorders or HIV infection, liver diseases other than NAFLD, including viral hepatitis (detected with positive serum hepatitis B surface antigen or hepatitis C viral RNA), Wilson's disease, hemochromatosis, glycogen storage disease, alpha-1 antitrypsin defi ciency, autoimmune hepatitis, and cholestatic or vascular liver disease, clinical or biochemical evidence of decompensated liver disease (Child-Pugh score >7 points), evidence of active substance abuse, signifi cant systemic illnesses, contraindication(s) to MRI, pregnant or trying to become pregnant, or any other condition which, in the investigator's opinion, may aff ect the patient's competence or compliance in completing the study.
Clinical research assessment
All patients received clinical assessments at the UCSD NAFLD Research Center. A detailed history was obtained from all patients. A physical exam, which included vital signs, height, weight, and anthropometric measurements, was performed by a trained clinical investigator. Body mass index was defi ned as the body weight (in kilograms) divided by height (in meters) squared. Alcohol consumption was documented in outside clinical visits and confi rmed in the research clinic using the Alcohol Use Disorders Identifi cations Test and the Skinner questionnaire, both of which are validated tools to screen for heavy drinking and/or active alcohol abuse or dependence. A detailed history of medications was obtained and no patient took medications known or suspected to cause steatosis or steatohepatitis. Other causes of liver disease were systemically ruled out using detailed history and laboratory data. Subjects underwent the following biochemical tests: aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase, total bilirubin, direct bilirubin, albumin, hemoglobin A1c, fasting glucose, insulin, homeostatic model assessment of insulin resistance, prothrombin time, international normalized ratio, fasting lipid panel, free fatty acids, C-reactive protein, and platelet count. homeostatic model assessment of insulin resistance was defi ned as the product of glucose and insulin divided by 405.
Histologic assessment
All patients underwent a systemic liver biopsy evaluation by an experienced liver pathologist blinded to the patients' laboratory and radiologic data. was used for this study. Hepatic fi brosis was scored on a fi ve-point scale (0, 1, 2, 3, 4), with advanced fi brosis defi ned as stage 3-4 fi brosis. Hepatic steatosis and lobular infl ammation were scored on four-point scales (0, 1, 2, 3) and hepatic ballooning was scored on a three-point scale (0, 1, 2). Th e NAFLD activity score (NAS score) was the sum of the steatosis, lobular infl ammation, and ballooning scores and ranged from 0 to 8. NASH was scored on a three-point scale (non-NASH, borderline NASH, and defi nite NASH). Patients with both borderline NASH and defi nite NASH were classifi ed as having NASH for the purpose of this study. Th e average (±s.d.) of biopsy size and number of portal triads was 23.2 (±9.5) mm and 13.7 (±5.9) mm, respectively. 10/100 (10%) of the cohort had biopsy lengths shorter than 15 mm.
Outcome measures
Th e primary outcome was advanced fi brosis (stage 3 and 4 fi brosis). Th e secondary outcomes were the remaining dichotomized fi brosis stages: stage 0 vs. stage 1-4 fi brosis, stage 0-1 vs. stage 2-4 fi brosis, and stage 0-3 vs. stage 4 fi brosis.
Magnetic resonance imaging
MRI was performed using a 3T research scanner (GE Signa EXCITE HDxt; GE Healthcare, Waukesha, WI). Patients were instructed to fast for at least four hours before exam to reduce potential physiologic confounding factors. MRE was performed to assess hepatic stiff ness.
Magnetic resonance elastography
MRE was performed with a modifi ed advanced version of 2D-MRE similar to the commercially available "MR-touch" product from GE Healthcare and a prototype 3D-MRE implementation developed at the Mayo Clinic ( 27, (35) (36) (37) (38) .
MRE data acquisition
2D-and 3D-MRE were performed using the standard shear-wave frequency of 60 Hz used in commercial versions of the technique. 3D-MRE data were also obtained using a shear-wave frequency of 40 Hz. Th e exams were performed as previously described in the literature ( 35, 36 ) . A device for applying mechanical vibrations during scanning was applied to the body wall anterior to the liver and held in place with an elastic belt. Total imaging time for 2D-and 3D-MRE at 60 Hz and 3D-MRE at 40 Hz was less than 3.5 min. 2D-MRE was performed at a driver frequency of 60 Hz. A motion-sensitized gradient-recalled-echo imaging sequence was performed at four diff erent phase off sets during one 16-s breath hold. Th is was repeated at four separate axial slices (10 mm thick, 10 mm interslice gap) at the widest transverse section of the liver with short recovery in between. Acquisition parameters for each axial slice were as follows: 1 motion-sensitizing direction (superior to inferior); repetition time, 50 ms; echo time, 20.2 ms; fl ip angle (FA), 30°; matrix, 256×64; fi eld of view, 38×38 cm 2 ; onesignal average; receiver bandwidth ±31.25 kHz; and parallel imaging acceleration factor, 2.
3D-MRE was performed separately at 40 and 60 Hz driver frequencies. For each exam, a separate motion-sensitized, multi-slice, spin-echo echo-planar-imaging sequence was performed to capture shear-wave displacements along the x -, y -, and z -directions for a single phase-off set. Data acquisition for the three sets of wave data was performed during one 21-s breath-hold scan, and then repeated at three diff erent phase off sets. Th e acquisition parameters for both 40 ; receiver bandwidth ±250 kHz; and parallel imaging acceleration factor, 3.
MRE processing
For 2D-MRE, processing was automatically performed on the imager using the same algorithm that is used in commercial implementations of the technology, producing liver stiff ness maps (called elastograms) ( 39 ) . Th ese maps display the spatial distribution of a stiff ness parameter called the magnitude of the complex shear modulus. For 3D-MRE, a prototype 3D direct inversion algorithm with characteristics similar to the 2D algorithm was used.
Elastograms were transferred offl ine for analysis ( 40, 41 ) by a trained image analyst with at least 6 months of experience working with MRE. Th e image analyst drew regions of interest on the elastograms, including only liver parenchyma while avoiding liver edges, large blood vessels, and artifacts. Th e per-pixel stiff ness values across regions of interest were calculated and automatically outputted to an electronic spreadsheet.
Duration between MRE and liver biopsy
Th e median (interquartile range) time interval between MRE and biopsy was 46 (44) days.
Statistical analyses
An experienced biostatistical analyst (T.W.) performed the statistical analyses for this study under the supervision of a faculty statistician (A.G.) using "R" statistical computing soft ware (R version 2.15.1 [2012-06-22] ; R: a language and environment for statistical computing; R Foundation for Statistical Computing, Vienna, Austria). Demographic, laboratory, histological, and imaging data were summarized using mean and standard deviation for continuous measures and counts and percentages for categorical measures. A two-tailed P -value ≤0.05 was considered statistically signifi cant.
Main analysis and cross-validation
Receiver operating characteristic (ROC) curve analysis was performed to assess the utility of 3D-MRE at 40 and 60 Hz and 2D-MRE at 60 Hz for diagnosing advanced fi brosis (stage 3-4 fi brosis). Th e area under ROC curves (AUROCs) were calculated for 3D-MRE and 2D-MRE. Th e cutoff value needed to obtain a minimum specifi city of 0.9 was determined, and the following performance parameters were calculated: sensitivity, specifi city, positive predictive value (PPV), and negative predictive valve (NPV). Sixfold cross-validation was performed on the threshold selection method for 3D-MRE and 2D-MRE and the same performance parameters were calculated. 95% Confi dence LIVER Novel 3D-MRE for NAFLD Advanced Fibrosis Diagnosis intervals (CIs) were calculated for both raw and cross-validated performance parameters. Bootstrap-based comparisons were used to compare the AUROC of 3D-MRE at 40 and 60 Hz against the AUROC of 2D-MRE at 60 Hz.
Secondary analyses
Additional ROC analysis was performed to determine the AUROC, classifying threshold, performance parameter with 95% CIs, and cross-validated performance parameters for other diagnostic end points: any fi brosis (stage 0 vs. 1-4), mild fi brosis (stage 0-1 vs. 2-4), moderate fi brosis (stage 0-2 vs. 3-4), and cirrhosis (stage 0-3 vs. 4). Th e aspartate aminotransferase to Platelet Ratio Index (APRI) score was calculated using previously published formula ( 42 ) and the AUROCs of APRI vs. MRE was compared using the DeLong test ( 43 ) .
RESULTS
Baseline characteristics
One hundred consecutive patients with biopsy-proven NAFLD and MRE were prospectively enrolled. Th e mean (±s.d.) of age and body mass index was 50.2 (±13.6) and 32.1 (±5.0), respectively. Baseline characteristics, including demographical, biochemical, histological, and imaging data, are summarized in Table 1 . A total of 163 patients were observed at the NAFLD Translational Unit, although 63 were excluded because 3D-MRE and/ or 2D-MRE were not performed. In our cohort of 100 patients, 2D-MRE (60 Hz), 3D-MRE (60 Hz), and 3D-MRE (40 Hz) were not obtained in 1, 2, and 8 patients, respectively, due to patient schedule.
Distribution of fi brosis stage
In all, 41, 32, 12, 10, and 5 patients had stage 0, 1, 2, 3, and 4 fi brosis, respectively. A total of 15 out of 100 patients (15.0% of total) had advanced fi brosis.
Accuracy of 2D-MRE for assessing advanced fi brosis
Th e AUROC for distinguishing advanced fi brosis from stage 0-2 fi brosis was 0.921 ( P <0.0001; Figure 1a ) . At a raw threshold of 3.80 kPa ( Figure 2a Table 2 ). 2D-MRE (60 Hz) misclassifi ed 5 out of 84 patients without advanced fi brosis and 2 out of 15 patients with advanced fi brosis.
Accuracy of 3D-MRE
As shown in Figure 1b , the AUROC for distinguishing advanced fi brosis from stage 0-2 fi brosis for 3D-MRE (60 Hz) is 0.927 ( P <0.0001). At a raw threshold of 3.40 kPa ( Figure 2b Table 2 ). 3D-MRE (60 Hz) misclassifi ed 3 out of 83 patients without advanced fi brosis and 2 out of 15 patients with advanced fi brosis. Loomba et al.
Accuracy of 3D-MRE at 40 Hz
As shown in Figure 1c , the AUROC for distinguishing advanced fi brosis from stage 0-2 fi brosis was 0.981 ( P <0.0001) for 3D-MRE (40 Hz). At a raw threshold of 2.43 kPa ( Figure 2c Table 2 ). 3D-MRE (40 Hz) misclassifi ed 5 out of 79 patients without advanced fi brosis but correctly classifi ed 13 out of 13 patients with advanced fi brosis.
Cross-validated 2D and 3D-MRE for advanced fi brosis diagnosis
Stratifi ed sixfold cross-validation was performed for 2D-MRE and 3D-MRE in diagnosing advanced fi brosis. Th e sensitivity, specifi city, PPV, and NPV of the cross-validated models were similar to that of the raw models ( Table 2 ).
Comparison of 2D-MRE vs. 3D-MRE for advanced fi brosis diagnosis
In bootstrap-based comparisons, there were no signifi cant difference in diagnostic performance, as assessed by the AUROC, between 2D-MRE (60 Hz) and 3D-MRE (60 Hz; 95% CI: −0.004 to 0.259). 3D-MRE (40 Hz) had higher AUROC than 2D-MRE (60 Hz) for diagnosing advanced fi brosis (95% CI: 0.001-0.223, P <0.05; Figure 3 ). Representative elastograms and biopsy slides of a patient with stage 4 fi brosis (cirrhosis) are shown for 2D-MRE (60 Hz), 3D-MRE (40 Hz), and 3D-MRE (60 Hz; Figure 4 ).
3D-and 2D-MRE for diagnosis of other fi brosis stages and NASH
Th e accuracy of 3D-and 2D-MRE for discriminating other stages of liver fi brosis, with the estimated cutoff s, is summarized in Table 3 . MRE had AUROCs of 0.981, 0.983, and 0.993 for 
Comparison of MRE and APRI for diagnosis of advanced fi brosis
Th e AUROC of APRI for diagnosing advanced fi brosis was 0.719 ( P =0.007). In direct comparisons of AUROCs using the DeLong test, 2D-MRE (60 Hz), 3D-MRE (60 Hz), and 3D-MRE (40 Hz) all had signifi cantly higher AUROCs than APRI for diagnosing advanced fi brosis, with P -values of 0.018, 0.017, and <0.001, respectively.
DISCUSSION
Main fi ndings
Using a prospective cohort design of 100 patients, this study demonstrated that both 2D-MRE and 3D-MRE are highly accurate for diagnosing advanced fi brosis in patients with biopsyproven NAFLD. 2D-and 3D-MRE are also highly accurate for the diagnosis of NAFLD-associated cirrhosis. In a head-to-head comparison, 3D-MRE at 40 Hz is signifi cantly better than 2D-MRE at 60 Hz for advanced fi brosis detection. In this study, the diagnostic performance obtained with a shear wave frequency of 40 Hz was slightly higher than at 60 Hz. AUROC, area under receiver operating characteristic curve; CV, cross-validated; MRE, magnetic resonance elastography; NPV, negative predictive value; PPV, positive predictive value; sens, sensitivity; spec, specifi city; 2D, two-dimensional; 3D, three-dimensional. lence of obesity in NAFLD patients ( 3, (5) (6) (7) . Th e diagnostic accuracy of MRE does not appear to be impacted by obesity or liver fat content ( 28, 35 ) . However, magnetic resonance technology is contraindicated in some patients, such as those with implanted electronic devices such as pacemakers or claustrophobia, and other imaging techniques may need to be pursued in these patients instead for noninvasive advanced fi brosis diagnosis ( 47 ) .
3D-MRE(40 Hz
Clinical prediction rules, including the NAFLD fi brosis score ( 17 ), FIB-4 (ref. 18 ) , and APRI ( 42 ) may be used to predict advanced fi brosis in NAFLD patients ( 1, 20, 21, 48 ) . However, these clinical prediction rules have less diagnostic accuracy than MRE ( 48 ) and may have indeterminate ranges, and more accurate tests are needed. Although a low clinical prediction rule cutoff may be used to rule out advanced fi brosis and a high cutoff to rule in advanced fi brosis in NAFLD patients, 3D-MRE may provide additional diagnostic utility in patients with indeterminate clinical prediction rule scores.
Strengths and limitations
Th e strength of this study lies in its use of a prospective, wellcharacterized cohort of NAFLD patients with clinical indications for liver biopsy. Th e study was performed by experienced clinical investigators in a specialized NAFLD translational research unit for both clinical and radiologic research in NAFLD, and patients Th e non-invasive diagnosis of advanced fi brosis in NAFLD patients remains a major unmet need. Compared with 2D-MRE, 3D-MRE allows for improved assessment of spatial patterns of hepatic fi brosis and focal lesions. However, 2D-MRE is simpler to implement compared with 3D-MRE. Th is study shows that using the standard shear-wave frequency of 60 Hz, both 2D-and 3D-MRE have equivalent diagnostic performance and are highly eff ective in screening for advanced fi brosis in NAFLD patients. We propose that MRE is an accurate diagnostic test for the noninvasive diagnosis of advanced fi brosis and cirrhosis in NAFLD patients, and that both 2D-and 3D-MRE are highly eff ective for this purpose.
In context of published literature
Th is is the fi rst prospective study to evaluate the diagnostic utility of 3D-MRE for diagnosing advanced fi brosis in NAFLD patients. It shows 3D-MRE to be highly accurate for diagnosing advanced fi brosis. Th is study is consistent with previous studies showing 2D-MRE to also be highly accurate for advanced fi brosis diagnosis in NAFLD patients ( 27, 28 ) . Although ultrasound-based imaging techniques may be useful for assessing hepatic fat volume in NAFLD patients ( 44 ) , their utility in assessing advanced fi brosis is limited due to their high unreliable rates in obese patients ( 1,22-25,45,46 ) . Th is may be problematic given the high preva- were carefully excluded for other causes of liver disease before enrolling in the study. Th ere is a short time interval (46 days) between biopsy and imaging. Liver biopsy, the gold standard for this study, was scored using the NASH CRN histological scoring system, which is well-validated for use in NAFLD patients. Th is is the fi rst prospective study of biopsy-proven NAFLD that compares 3D-MRE vs. 2D-MRE in a large cohort of uniquely wellcharacterized patients. However, we acknowledge following limitations. It is a crosssectional analysis of a prospective cohort and does not longitudinally look at changes in fi brosis over time. Th e diagnostic accuracy of 3D-and 2D-MRE was compared with biopsy, which may be prone to sampling variability. Since the study was performed at a single center skilled in working with NAFLD patients, its generalizability in other clinical settings is unknown. Th e costeff ectiveness of 3D-MRE compared with 2D-MRE and biopsy is also unknown, although at our center MRE is cheaper to perform than biopsy without the associated morbidity and mortality. MRE may be contraindicated in some patients, such as those with metal implants or claustrophobia, thus potentially limiting its use in some NAFLD patients.
Impact on future research
Th is study demonstrates both 2D-and 3D-MRE are highly accurate for advanced fi brosis diagnosis in a prospective cohort of patients with biopsy-proven NAFLD. Th e evidence that MRE performed at a lower shear-wave frequency of 40 Hz may provide increased diagnostic performance provides motivation for further investigation of this issue.
In summary, this study provides evidence that the diagnostic performance of 2D-MRE, which is technically undemanding, is similar to that of full 3D wave fi eld MRE in noninvasive screening of NAFLD-associated advanced fi brosis in a community setting. Further multicenter studies are needed to evaluate the utility of 2D-and 3D-MRE for monitoring longitudinal changes in liver fi brosis in both natural history studies and intervention trials. Th e cost-eff ectiveness of utilizing 3D-MRE compared with 2D-MRE and/or biopsy must also be evaluated to devise comprehensive, cost-effi cient screening strategies for NAFLD-associated advanced fi brosis. 
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WHAT IS CURRENT KNOWLEDGE
✓ Two-dimensional-magnetic resonance elastography (2D-MRE) is accurate in detecting advanced fi brosis in NAFLD.
✓ Three-dimensional-magnetic resonance elastography (3D-MRE) can evaluate a larger volume of the liver than 2D-MRE.
✓ No data are available regarding the diagnostic test characteristics of 3D-MRE and whether there is an advantage of evaluating a larger volume of the liver in 3D-MRE and if it further improves diagnostic test accuracy over 2D-MRE in the detection of advanced fi brosis in well-characterized patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD).
WHAT IS NEW HERE
✓ First prospective study to show the diagnostic accuracy of 3D-MRE at various frequencies in patients with NAFLD who have a clinical indication for a liver biopsy.
✓ First head to head comparative study comparing 2D-MRE vs. 3D-MRE.
✓ 3D-MRE at 40 Hz is signifi cantly more accurate than 2D-MRE at 60 Hz for diagnosis of advanced fi brosis in NAFLD with liver biopsy as the gold standard.
